Literature DB >> 31750025

Cerebral degeneration in amyotrophic lateral sclerosis: A prospective multicenter magnetic resonance spectroscopy study.

Ojas Srivastava1, Chris Hanstock1, Sneha Chenji1, Dennell Mah1, Dean Eurich1, Daniel Ta1, Peter Seres1, Collin Luk1, Lorne Zinman1, Agessandro Abrahao1, Simon J Graham1, Angela Genge1, Lawrence Korngut1, Richard Frayne1, Sanjay Kalra1.   

Abstract

BACKGROUND: We investigated cerebral degeneration and neurochemistry in patients with amyotrophic lateral sclerosis (ALS) using magnetic resonance spectroscopy (MRS).
METHODS: We prospectively studied 65 patients and 43 age-matched healthy controls. Participants were recruited from 4 centers as part of a study in the Canadian ALS Neuroimaging Consortium. All participants underwent single-voxel proton MRS using a protocol standardized across all sites. Metabolites reflecting neuronal integrity (total N-acetyl aspartyl moieties [tNAA]) and gliosis (myo-inositol [Ino]), as well as creatine (Cr) and choline (Cho), were quantified in the midline motor cortex and midline prefrontal cortex. Comparisons were made between patients with ALS and healthy controls. Metabolites were correlated with clinical measures of upper motor neuron dysfunction, disease progression rate, and cognitive performance.
RESULTS: In the motor cortex, tNAA/Cr, tNAA/Cho, and tNAA/Ino ratios were reduced in the ALS group compared with controls. Group differences in tNAA/Cr and tNAA/Cho in the prefrontal cortex displayed reduced ratios in ALS patients; however, these were not statistically significant. Reduced motor cortex ratios were associated with slower foot tapping rate, whereas only motor tNAA/Ino was associated with finger tapping rate. Disease progression rate was associated with motor tNAA/Cho. Verbal fluency, semantic fluency, and digit span forwards and backwards were associated with prefrontal tNAA/Cr.
CONCLUSIONS: This study demonstrates that cerebral degeneration in ALS is more pronounced in the motor than prefrontal cortex, that multicenter MRS studies are feasible, and that motor tNAA/Ino shows promise as a potential biomarker.
© 2019 American Academy of Neurology.

Entities:  

Year:  2019        PMID: 31750025      PMCID: PMC6814429          DOI: 10.1212/CPJ.0000000000000674

Source DB:  PubMed          Journal:  Neurol Clin Pract        ISSN: 2163-0402


  36 in total

1.  The syndrome of cognitive impairment in amyotrophic lateral sclerosis: a population-based study.

Authors:  Julie Phukan; Marwa Elamin; Peter Bede; Norah Jordan; Laura Gallagher; Susan Byrne; Catherine Lynch; Niall Pender; Orla Hardiman
Journal:  J Neurol Neurosurg Psychiatry       Date:  2011-08-11       Impact factor: 10.154

2.  Stages of pTDP-43 pathology in amyotrophic lateral sclerosis.

Authors:  Johannes Brettschneider; Kelly Del Tredici; Jon B Toledo; John L Robinson; David J Irwin; Murray Grossman; EunRan Suh; Vivianna M Van Deerlin; Elisabeth M Wood; Young Baek; Linda Kwong; Edward B Lee; Lauren Elman; Leo McCluskey; Lubin Fang; Simone Feldengut; Albert C Ludolph; Virginia M-Y Lee; Heiko Braak; John Q Trojanowski
Journal:  Ann Neurol       Date:  2013-06-19       Impact factor: 10.422

3.  Reduction in metabolite transverse relaxation times in amyotrophic lateral sclerosis.

Authors:  Christopher C Hanstock; Valerie A Cwik; W R Wayne Martin
Journal:  J Neurol Sci       Date:  2002-06-15       Impact factor: 3.181

4.  Estimation of brainstem neuronal loss in amyotrophic lateral sclerosis with in vivo proton magnetic resonance spectroscopy.

Authors:  V A Cwik; C C Hanstock; P S Allen; W R Martin
Journal:  Neurology       Date:  1998-01       Impact factor: 9.910

Review 5.  Amyotrophic lateral sclerosis - frontotemporal spectrum disorder (ALS-FTSD): Revised diagnostic criteria.

Authors:  Michael J Strong; Sharon Abrahams; Laura H Goldstein; Susan Woolley; Paula Mclaughlin; Julie Snowden; Eneida Mioshi; Angie Roberts-South; Michael Benatar; Tibor HortobáGyi; Jeffrey Rosenfeld; Vincenzo Silani; Paul G Ince; Martin R Turner
Journal:  Amyotroph Lateral Scler Frontotemporal Degener       Date:  2017-01-05       Impact factor: 4.092

6.  Proton magnetic resonance spectroscopy of the motor cortex in 70 patients with amyotrophic lateral sclerosis.

Authors:  C Pohl; W Block; J Karitzky; F Träber; S Schmidt; C Grothe; R Lamerichs; H Schild; T Klockgether
Journal:  Arch Neurol       Date:  2001-05

7.  Reduced NAA in motor and non-motor brain regions in amyotrophic lateral sclerosis: a cross-sectional and longitudinal study.

Authors:  R R Rule; J Suhy; N Schuff; D F Gelinas; R G Miller; M W Weiner
Journal:  Amyotroph Lateral Scler Other Motor Neuron Disord       Date:  2004-09

8.  Multinuclear NMR studies on the energy metabolism of glial and neuronal cells.

Authors:  A Brand; C Richter-Landsberg; D Leibfritz
Journal:  Dev Neurosci       Date:  1993       Impact factor: 2.984

9.  Frontal lobe abnormalities on MRS correlate with poor letter fluency in ALS.

Authors:  Colin Quinn; Lauren Elman; Leo McCluskey; Katelin Hoskins; Chafic Karam; John H Woo; Harish Poptani; Sumei Wang; Sanjeev Chawla; Scott E Kasner; Murray Grossman
Journal:  Neurology       Date:  2012-07-25       Impact factor: 9.910

10.  Objective tests for upper motor neuron involvement in amyotrophic lateral sclerosis (ALS).

Authors:  P Kaufmann; S L Pullman; D C Shungu; S Chan; A P Hays; M L Del Bene; M A Dover; M Vukic; L P Rowland; H Mitsumoto
Journal:  Neurology       Date:  2004-05-25       Impact factor: 9.910

View more
  2 in total

1.  Progressive Neurochemical Abnormalities in Cognitive and Motor Subgroups of Amyotrophic Lateral Sclerosis: A Prospective Multicenter Study.

Authors:  Daniel Ta; Abdullah Ishaque; Ojas Srivastava; Chris Hanstock; Peter Seres; Dean T Eurich; Collin Luk; Hannah Briemberg; Richard Frayne; Angela L Genge; Simon J Graham; Lawrence Korngut; Lorne Zinman; Sanjay Kalra
Journal:  Neurology       Date:  2021-06-14       Impact factor: 11.800

2.  Imaging Neurochemistry and Brain Structure Tracks Clinical Decline and Mechanisms of ALS in Patients.

Authors:  Ovidiu C Andronesi; Katharine Nicholson; Kourosh Jafari-Khouzani; Wolfgang Bogner; Jing Wang; James Chan; Eric A Macklin; Mark Levine-Weinberg; Christopher Breen; Michael A Schwarzschild; Merit Cudkowicz; Bruce R Rosen; Sabrina Paganoni; Eva-Maria Ratai
Journal:  Front Neurol       Date:  2020-12-03       Impact factor: 4.003

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.